ArticleScientific reports2025
A ZnO-TiO2-Amygdalin nanocomposite for bone regeneration and antimicrobial activity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By decreasing bacterial infection and enhancing the bone repairing/healing process, nanomedicine has recently become an increasingly popular approach for addressing high infection risk and low bony reconstruction. Thus, in our study, we attempted to synthesize ZnO-TiO2-Amygdalin nanocomposite and investigate its effect against pathogenic microorganisms and also on the growth and differentiation of osteoblast cells. In this work, ZnO-TiO2-Amygdalin was formulated by co-precipitation. It was characterized by analytical techniques, which revealed the hydrodynamic radius of the nanocomposite to be 115 nm with a nanoflakes structure and Wurtzite hexagonal phase formation. According to the data, the ZnO-TiO2-Amygdalin nanocomposite surface matrix possesses a strong electrostatic interaction. The antimicrobial effects of ZnO-TiO2-Amygdalin nanocomposites were investigated in vitro against S. aureus, S. pneumoniae, K. pneumoniae, S. dysenteriae, and C. albicans, and dose-dependent inhibition of bacterial growth was observed. A time-dependent release of alkaline phosphatase was induced with calcium deposition by incubation ZnO-TiO2-Amygdalin nanocomposites at different doses in osteoblast-like cells (MG-63) exposed to ZnO-TiO2-Amygdalin nanocomposites. Ultimately, our data showed that due to its antimicrobial effect, increased osteoblast proliferation, stimulated ALP level, and calcium mineralization potential, ZnO-TiO2-Amygdalin nanocomposites could be effectively used in orthopedic traumas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.